Telomescan (OBP-401 and OBP-1101)


OBP-401 or TelomeScan is a genetically engineered adenovirus type 5 to detect tumor cells. TelomeScan has a human Telomerase Reverse Transcriptase (hTERT) gene promoter sequence in the upstream region of virus E1 gene which is responsible for replication of adenovirus, and a Green Fluorescent Protein (GFP) gene in E3 region under the control by cytomegalovirus promoter. TERT is a critical protein component of telomerase enzyme complex, and its expression is normally restricted in germ line cells or few stem cells including hematopoietic stem cells. Cancer cells are essentially acquired immortalized nature and express strong telomerase activity. Thus, OBP-401 can replicate only in telomerase activity-positive cells such as cancer cells by hTERT promoter activity-dependent E1/E2 gene expression, but not in telomerase activity-negative normal cells. Along with the increase in virus replication, concurrently-expressed GFP accumulates in hTERT-positive cells.
By utilizing OBP-401 ex vivo, it is possible to detect living circulating tumor cells (CTCs) in blood from cancer patients with high sensitivity and specificity. CTCs detection would be able to offer a tool for early detection of cancer, monitoring of therapeutic efficacy, monitoring of tumor recurrence, and selection of appropriate therapy to patients.
OBP-1101 is second generation of TelomeScan. Since TelomeScan has two issues to be improved, i.e. false negative and false positive. TelomeScan cannot be infected to some kind of cancer cells which lack adenovirus receptor "CAR" (coxackie-adenovirus receptor) on the cell surface. CAR-lacking cancer cells are regarded as "false negative". In contrast, TelomeScan generates false positive in some white blood cells having hTERT activity. To dissolve these issues, two genetic modifications including change in fibre gene and addition of four tandem-arrayed miR142-3p target sequences were added on OBP-401 vector sequence.

OBP-401 Outline Figure

Target indication

Detection of circulating tumor cells (CTCs)

Current status

Oncolys currently focuses on development of TelomeScan to detect CTCs in cancer patients and also provide clinical testing service to detect CTCs. Oncolys aims to get regulatory approval from Japanese PMDA and have been preparing regulatory consultation with the agency.
In December 2014, Oncolys out-licensed an exclusive license of OBP-1101 for South Korea to a listed South Korean company, WonikCube. WonikCube has been developing OBP-1101 in order to get regulatory approval in this territory.
In November 2015, Oncolys signed an exclusive license agreement for the North American territory with Liquid Biotech USA, Inc., founded by University of Pennsylvania and its professors. Liquid Biotech USA has been developing TelomeScan technology for providing CTC detection services to clinicians and pharmaceutical companies.